Navigation Links
Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity
Date:7/18/2008

Mechanism of Action of Metformin on Insulin Sensitization Poster Wins One

of Three Prizes

N. BILLERICA, Mass., July 18 /PRNewswire/ -- Seahorse Bioscience, Inc., leaders in real-time measurement of cellular bioenergetics announced today the receipt of The European Association for the Study of Obesity (EASO) poster award at the 16th European Congress on Obesity (ECO 2008) May 14-17, 2008 in Geneva, Switzerland.

The poster, Mechanism of Action of Metformin on Insulin Sensitization: Selective Fatty Acid Oxidation (FAO) over Glucose Oxidation via Inhibition of Complex I and Activation of AMP-activated protein kinase in C2C12 myocytes presented by author Dr. Min Wu of Seahorse Bioscience, was one of three posters to win the prestigious 2008 EASO Poster Prize. Poster Prize winners have already been listed on the EASO website (http://www.easoobesity.org) and will be highlighted in the Association's next e-newsletter.

"We are very pleased that EASO recognized our work on cellular mechanism of action of metformin," said David Ferrick, Vice President of Biology. "It is the bioenergetic analysis of fuel substrate selections that revealed the mechanism of action in different cell types, an analysis with the potential to be very powerful in the understanding and treatment of many other age-related diseases."

"It is unusual for an instrument manufacturer to be recognized for scientific contribution but Seahorse XF technology enables novel discoveries by bringing to light the importance of energy producing pathways of the cell," said Steven Chomicz, Vice President of Sales and Marketing for Seahorse Bioscience. "Dr. Wu used the features of the XF24 extracellular flux analyzer to perform an eloquent experiment which revealed metformin's, heretofore, unknown mechanism of action. This potential for award winning discoveries is why Seahorse XF technology is used by leading bioenergetic labs worldwide."

About Seahorse Bioscience, Inc.

Seahorse Bioscience is changing cancer, obesity, diabetes and age-related drug discovery programs the world over. Seahorse headquarters are located in North Billerica, Massachusetts. For more information, please visit http://www.seahorsebio.com.

If you would like more information about Seahorse Bioscience, Inc., or would like to schedule a meeting with Steve Chomicz, please contact Kristine Hunt at 978-671-1610.

Seahorse Bioscience, Inc.

Media Contact: Kristine Hunt

Phone: 978-671-1610


'/>"/>
SOURCE Seahorse Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
11. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
Breaking Biology News(10 mins):